Join our daily newsletter At The Bell to receive exclusive market insights
- ImpediMed (IPD) has completed 200,000 patient tests using the SOZO device since its launch in October 2017
- SOZO is a non-invasive, bioimpedance spectroscopy (BIS) device that delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds
- The company says it expects testing rates to continue to accelerate as it commercialises its heart and renal failure indications
- ImpediMed is up 9.09 per cent, trading at 12 cents
ImpediMed (IPD) says it has reached a milestone 200,000 patient tests for SOZO testing.
SOZO is a non-invasive, bioimpedance spectroscopy (BIS) device that delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO can capture an array of data over a wide spectrum of frequencies from three kilohertz to 1000 kilohertz to maximise patient health.
Over 200,000 patient tests have been conducted since its commercial launch in October 2017. More than 28,000 patient tests were conducted in Q2 FY21 alone.
It took the company 32 months to achieve the milestone of the first 100,000 patient tests. However, it powered through after its initial launch, testing the following 100,000 patients in just 13 months.
The company says it expects testing rates to continue to accelerate as they commercialise its heart and renal failure indications.
“This is a significant milestone for our company, but more importantly for the patients whose lives have been dramatically impacted by the reduction in lymphoedema rates from SOZO testing. For the company, we are building a large dataset which will be very valuable in providing new insights into the course and care of a large number of chronic disease states,” said Managing Director and CEO of ImpediMed, Richard Carreon.
ImpediMed is up 9.09 per cent, trading at 12 cents at 3:15 pm AEDT.
